Arcutis Biotherapeutics Inc (ARQT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.57B
Last updated: Nov 17, 2026 at 11:04 AM ET
Arcutis Biotherapeutics Inc (ARQT) P/E Ratio & Valuation Multiples
Arcutis Biotherapeutics (ARQT) trades at 129.3x trailing earnings and 7.0x sales. Its P/B of 14.6x is above its 5-year median of 7.1x. Its forward P/E is 31.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 305.3% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 129.3x |
| Forward P/E | 31.9x |
| Price to sales | 7.0x |
| Price to book | 14.6x |
| EV/EBITDA | 114.9x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 14.6x | 7.1x | N/A |
Valuation History
Over the 4 of the 6 year ends shown that have a P/S, its P/S ranged from 3.6x in 2023 to 241.5x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $29.04 | 10.0x | 20.8x |
| 2024 | $13.93 | 8.5x | 10.7x |
| 2023 | $3.23 | 3.6x | 3.4x |
| 2022 | $14.80 | 241.5x | 4.3x |
| 2021 | $20.74 | N/A | 3.5x |
| 2020 | $28.13 | N/A | 4.5x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ARQT
What is ARQT's forward P/E ratio?
Arcutis Biotherapeutics has a forward P/E ratio of 31.9x.
Is ARQT stock overvalued?
GNG's valuation label for ARQT is Fairly valued.
What is ARQT's price to sales ratio?
Arcutis Biotherapeutics has a price to sales ratio of 7.0x.
ARQT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors